Publications

Found 27 results
Filters: Keyword is HIV Envelope Protein gp120  [Clear All Filters]
2013
Doores KJ, Huber M, Le KM, Wang S-K, Doyle-Cooper C, Cooper A, Pantophlet R, Wong C-H, Nemazee D, Burton DR.  2013.  2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.. J Virol. 87(4):2234-41.
Crispin M, Bowden TA.  2013.  Antibodies expose multiple weaknesses in the glycan shield of HIV.. Nat Struct Mol Biol. 20(7):771-2.
Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M, Lifson JD et al..  2013.  Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.. Nature. 503(7475):277-80.
Ota T, Doyle-Cooper C, Cooper AB, Doores KJ, Aoki-Ota M, Le K, Schief WR, Wyatt RT, Burton DR, Nemazee D.  2013.  B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates.. J Immunol. 191(6):3179-85.
Doyle-Cooper C, Hudson KE, Cooper AB, Ota T, Skog P, Dawson PE, Zwick MB, Schief WR, Burton DR, Nemazee D.  2013.  Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10.. J Immunol. 191(6):3186-91.
Klasse P J, Depetris RS, Pejchal R, Julien J-P, Khayat R, Lee J H, Marozsan AJ, Cupo A, Cocco N, Korzun J et al..  2013.  Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.. J Virol. 87(17):9873-85.
Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang G-Y, M Joyce G et al..  2013.  Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.. Immunity. 39(2):245-58.
Pancera M, Shahzad-ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y et al..  2013.  Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.. Nat Struct Mol Biol. 20(7):804-13.
2011
Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, Gnanapragasam PNP, Abadir A, Seaman MS, Nussenzweig MC et al..  2011.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.. Science. 334(6060):1289-93.
Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE et al..  2011.  Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.. J Virol. 85(17):8954-67.
Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TYK, Velinzon K, Seaman MS, Nussenzweig MC.  2011.  Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.. PLoS One. 6(9):e24078.
Walker LM, Sok D, Nishimura Y, Donau O, Sadjadpour R, Gautam R, Shingai M, Pejchal R, Ramos A, Simek MD et al..  2011.  Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque.. Proc Natl Acad Sci U S A. 108(50):20125-9.
Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TYK, Pietzsch J, Fenyo D, Abadir A, Velinzon K et al..  2011.  Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.. Science. 333(6049):1633-7.
McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, Khayat R, Louder R, Pejchal R, Sastry M, Dai K et al..  2011.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.. Nature. 480(7377):336-43.
Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang Y K, Depetris RS, Marozsan AJ, Sanders RW et al..  2011.  Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.. Proc Natl Acad Sci U S A. 108(28):11440-5.

Pages